Insights

Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.

Our work is reader-supported. Sign up to our free or paid plans here.

Subcribe to Pα+
Visit the Pα+ Dashboard

The latest

Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley Says R-MDMA Met Safety Goal in SAD, Details Phase 3 Design for 5-MeO-DMT in TRD; Psilocybin for Smoking Cessation Study Published

March 11, 2026

Policy Round-Up: State Momentum, Congressional Signals, and Colorado’s Data Build-Out • RAND Survey: Americans Divided on Psilocybin Legalisation • Helus’ Phase 2a Study of Intravenous DMT in MDD Published in Nature Medicine • Transcend’s Phase 2 Study of Methylone in PTSD Publishes in JAMA Psychiatry • Large German Psilocybin Trial Misses Primary Endpoint • Latest Data from Aus Reports 188 Patients Treated • FDA’s ‘One Pivotal Trial’ Default • and more…

Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials

February 27, 2026

In this conversation with Psychedelic Alpha’s Josh Hardman, Dr. Terence Ching discusses his journey into the field and current work leading Yale’s psilocybin trials for OCD. He reflects on study design considerations, potential mechanisms of action, and some of the subjective phenomena observed during psilocybin sessions in those studies. Dr. Ching also explores what experience and data suggest about integrating psychedelics with evidence-based treatments like CBT and ACT.

Pα+ Psychedelic Bulletin #220: New State Bills; Congressional Mentions; Published Psilocybin, DMT, and Methylone Studies; RAND Polling Reveals 23% of Americans Support Legal Psilocybin Use

February 24, 2026

Policy Round-Up: State Momentum, Congressional Signals, and Colorado’s Data Build-Out • RAND Survey: Americans Divided on Psilocybin Legalisation • Helus’ Phase 2a Study of Intravenous DMT in MDD Published in Nature Medicine • Transcend’s Phase 2 Study of Methylone in PTSD Publishes in JAMA Psychiatry • Large German Psilocybin Trial Misses Primary Endpoint • Latest Data from Aus Reports 188 Patients Treated • FDA’s ‘One Pivotal Trial’ Default • and more…

Load more

The Library

Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.

The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.

It’s exclusively available to our Pα+ subscribers, with new content added regularly.

Subcribe to Pα+

Pα+ Library: Bifurcated Scheduling

December 6, 2023

Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.

Pα+ Library: Psychedelic REMS

November 15, 2023

Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.

The Psychedelic Practitioner

The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.

The Psychedelic Practitioner Issue 3: Dosing

February 10, 2026

The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments. In this Issue, we take a deep dive into psychedelic dosing and ceremony through interviews, research reviews, and practitioner perspectives.

The Psychedelic Practitioner Issue 2: Preparation

December 11, 2025

The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments. In this Issue, we take a deep dive into the science and practice of psychedelic preparation through interviews, research reviews, and practitioner perspectives.

The Psychedelic Practitioner: Issue 1

October 9, 2025

The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.

The Psychedelic News Feed Archives

Archived versions of our Psychedelic News Feed.

Load more